Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Nuclear Medicine and Molecular Imaging

21.02.2024 | Review

Recent Update on PET/CT Radiotracers for Imaging Cerebral Glioma

verfasst von: Dongwoo Kim, Suk-Hyun Lee, Hee Sung Hwang, Sun Jung Kim, Mijin Yun

Erschienen in: Nuclear Medicine and Molecular Imaging

Einloggen, um Zugang zu erhalten

Abstract

Positron emission tomography/computed tomography (PET/CT) has dramatically altered the landscape of noninvasive glioma evaluation, offering complementary insights to those gained through magnetic resonance imaging (MRI). PET/CT scans enable a multifaceted analysis of glioma biology, supporting clinical applications from grading and differential diagnosis to mapping the full extent of tumors and planning subsequent treatments and evaluations. With a broad array of specialized radiotracers, researchers and clinicians can now probe various biological characteristics of gliomas, such as glucose utilization, cellular proliferation, oxygen deficiency, amino acid trafficking, and reactive astrogliosis. This review aims to provide a recent update on the application of versatile PET/CT radiotracers in glioma research and clinical practice.
Literatur
1.
Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol. 2015;17 Suppl 4:iv1-iv62.
2.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.CrossRefPubMed
3.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231–51.CrossRefPubMedPubMedCentral
4.
Singhal T, Narayanan TK, Jacobs MP, Bal C, Mantil JC. 11C-Methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med. 2012;53:1709–15.CrossRefPubMed
5.
Heiss WD. PET in gliomas. Overview of current studies. Nuklearmedizin. 2014;53:163–71; quiz N32.
6.
Dhermain F. Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches. Chin J Cancer. 2014;33:16–24.CrossRefPubMedPubMedCentral
7.
Kosaka N, Tsuchida T, Uematsu H, Kimura H, Okazawa H, Itoh H. 18F-FDG PET of common enhancing malignant brain tumors. AJR Am J Roentgenol. 2008;190:W365–9.CrossRefPubMed
8.
Kim D, Kim S, Kim SH, Chang JH, Yun M. Prediction of overall survival based on isocitrate dehydrogenase 1 mutation and 18F-FDG uptake on PET/CT in patients with cerebral gliomas. Clin Nucl Med. 2018;43:311–6.CrossRefPubMed
9.
Cui M, Zorrilla-Veloz RI, Hu J, Guan B, Ma X. Diagnostic accuracy of PET for differentiating true glioma progression from post treatment-related changes: a systematic review and meta-analysis. Front Neurol. 2021;12: 671867.CrossRefPubMedPubMedCentral
10.
Treglia G, Muoio B, Trevisi G, Mattoli MV, Albano D, Bertagna F, et al. Diagnostic performance and prognostic value of PET/CT with different tracers for brain tumors: a systematic review of published meta-analyses. Int J Mol Sci. 2019;20:4669.
11.
Ouyang ZQ, Zheng GR, Duan XR, Zhang XR, Ke TF, Bao SS, et al. Diagnostic accuracy of glioma pseudoprogression identification with positron emission tomography imaging: a systematic review and meta-analysis. Quant Imaging Med Surg. 2023;13:4943–59.CrossRefPubMedPubMedCentral
12.
Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46:540–57.CrossRefPubMed
13.
Piccardo A, Albert NL, Borgwardt L, Fahey FH, Hargrave D, Galldiks N, et al. Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2022;49:3852–69.CrossRefPubMedPubMedCentral
14.
Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B, et al. EANM procedure guidelines for brain PET imaging using [(18)F]FDG, version 3. Eur J Nucl Med Mol Imaging. 2022;49:632–51.CrossRefPubMed
15.
Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology. 1982;32:1323–9.CrossRefPubMed
16.
Smith TA. The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation. Nucl Med Biol. 2001;28:1–4.ADSCrossRefPubMed
17.
Omuro AM, Leite CC, Mokhtari K, Delattre JY. Pitfalls in the diagnosis of brain tumours. Lancet Neurol. 2006;5:937–48.CrossRefPubMed
18.
Demetriades AK, Almeida AC, Bhangoo RS, Barrington SF. Applications of positron emission tomography in neuro-oncology: a clinical approach. Surgeon. 2014;12:148–57.CrossRefPubMed
19.
Kim D, Ko HY, Lee S, Lee YH, Ryu S, Kim SY, et al. Glucose loading enhances the value of (18)F-FDG PET/CT for the characterization and delineation of cerebral gliomas. Cancers (Basel). 2020;12:1977.
20.
Johnson JM, Chen MM, Rohren EM, Prabhu S, Chasen B, Mawlawi O, et al. Delayed FDG PET provides superior glioblastoma conspicuity compared to conventional image timing. Front Neurol. 2021;12: 740280.CrossRefPubMedPubMedCentral
21.
Lee SM, Koh HJ, Park DC, Song BJ, Huh TL, Park JW. Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med. 2002;32:1185–96.CrossRefPubMed
22.
23.
Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116:597–602.CrossRefPubMed
24.
Chen JR, Yao Y, Xu HZ, Qin ZY. Isocitrate dehydrogenase (IDH)1/2 mutations as prognostic markers in patients with glioblastomas. Medicine (Baltimore). 2016;95: e2583.CrossRefPubMed
25.
Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432–45.PubMed
26.
Isselbacher KJ. Sugar and amino acid transport by cells in culture–differences between normal and malignant cells. N Engl J Med. 1972;286:929–33.CrossRefPubMed
27.
Busch H, Davis JR, Honig GR, Anderson DC, Nair PV, Nyhan WL. The uptake of a variety of amino acids into nuclear proteins of tumors and other tissues. Cancer Res. 1959;19:1030–9.PubMed
28.
Miyagawa T, Oku T, Uehara H, Desai R, Beattie B, Tjuvajev J, et al. “Facilitated” amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab. 1998;18:500–9.CrossRefPubMed
29.
Kinoshita M, Arita H, Goto T, Okita Y, Isohashi K, Watabe T, et al. A novel PET index, 18F-FDG-11C-methionine uptake decoupling score, reflects glioma cell infiltration. J Nucl Med. 2012;53:1701–8.CrossRefPubMed
30.
Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006;47:904–11.PubMed
31.
Lau EW, Drummond KJ, Ware RE, Drummond E, Hogg A, Ryan G, et al. Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J Clin Neurosci. 2010;17:43–9.CrossRefPubMed
32.
Chung JK, Kim YK, Kim SK, Lee YJ, Paek S, Yeo JS, et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002;29:176–82.CrossRefPubMed
33.
Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, et al. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging. 2013;40:615–35.CrossRefPubMed
34.
Galldiks N, Kracht LW, Dunkl V, Ullrich RT, Vollmar S, Jacobs AH, et al. Imaging of non- or very subtle contrast-enhancing malignant gliomas with [(1)(1)C]-methionine positron emission tomography. Mol Imaging. 2011;10:453–9.CrossRefPubMed
35.
Falk Delgado A, Falk DA. Discrimination between primary low-grade and high-grade glioma with (11)C-methionine PET: a bivariate diagnostic test accuracy meta-analysis. Br J Radiol. 2018;91:20170426.CrossRefPubMedPubMedCentral
36.
Mattoli MV, Trevisi G, Scolozzi V, Capotosti A, Cocciolillo F, Marini I, et al. Dynamic (11)C-methionine PET-CT: prognostic factors for disease progression and survival in patients with suspected glioma recurrence. Cancers (Basel). 2021;13:4777.
37.
Bag AK, Wing MN, Sabin ND, Hwang SN, Armstrong GT, Han Y, et al. (11)C-Methionine PET for identification of pediatric high-grade glioma recurrence. J Nucl Med. 2022;63:664–71.PubMedPubMedCentral
38.
Ninatti G, Sollini M, Bono B, Gozzi N, Fedorov D, Antunovic L, et al. Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas. Neuro Oncol. 2022;24:1546–56.CrossRefPubMedPubMedCentral
39.
Heiss P, Mayer S, Herz M, Wester HJ, Schwaiger M, Senekowitsch-Schmidtke R. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med. 1999;40:1367–73.PubMed
40.
Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40:205–12.PubMed
41.
Salber D, Stoffels G, Pauleit D, Oros-Peusquens AM, Shah NJ, Klauth P, et al. Differential uptake of O-(2–18F-fluoroethyl)-L-tyrosine, L-3H-methionine, and 3H-deoxyglucose in brain abscesses. J Nucl Med. 2007;48:2056–62.CrossRefPubMed
42.
Stober B, Tanase U, Herz M, Seidl C, Schwaiger M, Senekowitsch-Schmidtke R. Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells. Eur J Nucl Med Mol Imaging. 2006;33:932–9.CrossRefPubMed
43.
Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro Oncol. 2016;18:426–34.CrossRefPubMed
44.
Skoblar Vidmar M, Doma A, Smrdel U, Zevnik K, Studen A. The value of FET PET/CT in recurrent glioma with a different IDH mutation status: the relationship between imaging and molecular biomarkers. Int J Mol Sci. 2022;23:6787.
45.
Matsubara K, Watabe H, Kumakura Y, Hayashi T, Endres CJ, Minato K, et al. Sensitivity of kinetic macro parameters to changes in dopamine synthesis, storage, and metabolism: a simulation study for [(1)(8)F]FDOPA PET by a model with detailed dopamine pathway. Synapse. 2011;65:751–62.CrossRefPubMed
46.
Eidelberg D, Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, et al. Striatal 18F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab. 1993;13:881–8.CrossRefPubMed
47.
Youland RS, Kitange GJ, Peterson TE, Pafundi DH, Ramiscal JA, Pokorny JL, et al. The role of LAT1 in (18)F-DOPA uptake in malignant gliomas. J Neurooncol. 2013;111:11–8.CrossRefPubMed
48.
Zaragori T, Ginet M, Marie PY, Roch V, Grignon R, Gauchotte G, et al. Use of static and dynamic [(18)F]-F-DOPA PET parameters for detecting patients with glioma recurrence or progression. EJNMMI Res. 2020;10:56.CrossRefPubMedPubMedCentral
49.
Jansen NL, Schwartz C, Graute V, Eigenbrod S, Lutz J, Egensperger R, et al. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro Oncol. 2012;14:1473–80.CrossRefPubMedPubMedCentral
50.
Kim D, Chun JH, Kim SH, Moon JH, Kang SG, Chang JH, et al. Re-evaluation of the diagnostic performance of (11)C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas. Eur J Nucl Med Mol Imaging. 2019;46:1678–84.CrossRefPubMed
51.
Ponisio MR, McConathy JE, Dahiya SM, Miller-Thomas MM, Rich KM, Salter A, et al. Dynamic (18)F-FDOPA-PET/MRI for the preoperative evaluation of gliomas: correlation with stereotactic histopathology. Neurooncol Pract. 2020;7:656–67.PubMedPubMedCentral
52.
Pike VW, Eakins MN, Allan RM, Selwyn AP. Preparation of [1-11C]acetate–an agent for the study of myocardial metabolism by positron emission tomography. Int J Appl Radiat Isot. 1982;33:505–12.CrossRefPubMed
53.
Nicklas WJ, Clarke DD. Decarboxylation studies of glutamate, glutamine, and aspartate from brain labelled with [1-14C]acetate, L-[U-14C]-aspartate, and L-[U-14C]glutamate. J Neurochem. 1969;16:549–58.CrossRefPubMed
54.
55.
Cruz NF, Lasater A, Zielke HR, Dienel GA. Activation of astrocytes in brain of conscious rats during acoustic stimulation: acetate utilization in working brain. J Neurochem. 2005;92:934–47.CrossRefPubMed
56.
57.
Cerdan S, Kunnecke B, Seelig J. Cerebral metabolism of [1,2–13C2]acetate as detected by in vivo and in vitro 13C NMR. J Biol Chem. 1990;265:12916–26.CrossRefPubMed
58.
Hassel B, Sonnewald U, Fonnum F. Glial-neuronal interactions as studied by cerebral metabolism of [2-13C]acetate and [1-13C]glucose: an ex vivo 13C NMR spectroscopic study. J Neurochem. 1995;64:2773–82.CrossRefPubMed
59.
Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M, Woo DH, et al. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer’s disease. Nat Med. 2014;20:886–96.CrossRefPubMedPubMedCentral
60.
Chun H, Im H, Kang YJ, Kim Y, Shin JH, Won W, et al. Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer’s disease via H(2)O(2)(-) production. Nat Neurosci. 2020;23:1555–66.CrossRefPubMed
61.
Heo JY, Nam MH, Yoon HH, Kim J, Hwang YJ, Won W, et al. Aberrant tonic inhibition of dopaminergic neuronal activity causes motor symptoms in animal models of Parkinson’s disease. Curr Biol. 2020;30(276–91): e9.
62.
Nam MH, Cho J, Kwon DH, Park JY, Woo J, Lee JM, et al. Excessive astrocytic GABA causes cortical hypometabolism and impedes functional recovery after subcortical stroke. Cell Rep. 2020;32: 107975.CrossRefPubMed
63.
Nagashima G, Suzuki R, Asai J, Fujimoto T. Immunohistochemical analysis of reactive astrocytes around glioblastoma: an immunohistochemical study of postmortem glioblastoma cases. Clin Neurol Neurosurg. 2002;104:125–31.CrossRefPubMed
64.
Nam MH, Ko HY, Kim D, Lee S, Park YM, Hyeon SJ, et al. Visualizing reactive astrocyte-neuron interaction in Alzheimer’s disease using 11C-acetate and 18F-FDG. Brain. 2023;146:2957–74.CrossRefPubMed
65.
66.
Kato H, Okuno T, Isohashi K, Koda T, Shimizu M, Mochizuki H, et al. Astrocyte metabolism in multiple sclerosis investigated by 1-C-11 acetate PET. J Cereb Blood Flow Metab. 2021;41:369–79.CrossRefPubMed
67.
Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, et al. 11C-Acetate PET imaging of prostate cancer. J Nucl Med. 2002;43:181–6.PubMed
68.
Oyama N, Okazawa H, Kusukawa N, Kaneda T, Miwa Y, Akino H, et al. 11C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:422–7.CrossRefPubMed
69.
Ho CL, Yu SC, Yeung DW. 11C-Acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003;44:213–21.PubMed
70.
Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 2014;159:1603–14.CrossRefPubMedPubMedCentral
71.
Masui K, Cavenee WK, Mischel PS. mTORC2 and metabolic reprogramming in GBM: at the interface of genetics and environment. Brain Pathol. 2015;25:755–9.CrossRefPubMedPubMedCentral
72.
Liu RS, Chang CP, Chu LS, Chu YK, Hsieh HJ, Chang CW, et al. PET imaging of brain astrocytoma with 1–11C-acetate. Eur J Nucl Med Mol Imaging. 2006;33:420–7.CrossRefPubMed
73.
Yamamoto Y, Nishiyama Y, Kimura N, Kameyama R, Kawai N, Hatakeyama T, et al. 11C-Acetate PET in the evaluation of brain glioma: comparison with 11C-methionine and 18F-FDG-PET. Mol Imaging Biol. 2008;10:281–7.CrossRefPubMed
74.
Tsuchida T, Takeuchi H, Okazawa H, Tsujikawa T, Fujibayashi Y. Grading of brain glioma with 1–11C-acetate PET: comparison with 18F-FDG PET. Nucl Med Biol. 2008;35:171–6.CrossRefPubMed
75.
Kim S, Kim D, Kim SH, Park MA, Chang JH, Yun M. The roles of (11)C-acetate PET/CT in predicting tumor differentiation and survival in patients with cerebral glioma. Eur J Nucl Med Mol Imaging. 2018;45:1012–20.CrossRefPubMed
76.
Kim D, Cho A, Hwang SH, Jo K, Chang JH, Yun M. Choroid plexus as the best reference region for standardized uptake value analysis on C11-acetate PET/CT for grading and predicting prognosis in patients with cerebral gliomas. Nucl Med Mol Imaging. 2020;54:274–80.CrossRefPubMedPubMedCentral
77.
78.
Kim D, Chun JH, Yi JH, Ko HY, Chung JI, Lee M, et al. 11 C-Acetate PET/CT detects reactive astrogliosis helping glioma classification. Clin Nucl Med. 2022;47:863–8.CrossRefPubMed
79.
Diep YN, Park HJ, Kwon JH, Tran M, Ko HY, Jo H, et al. Astrocytic scar restricting glioblastoma via glutamate-MAO-B activity in glioblastoma-microglia assembloid. Biomater Res. 2023;27:71.CrossRefPubMedPubMedCentral
80.
Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, et al. 3′-Deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791–8.PubMed
81.
Salskov A, Tammisetti VS, Grierson J, Vesselle H. FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3′-deoxy-3′-[18F]fluorothymidine. Semin Nucl Med. 2007;37:429–39.CrossRefPubMed
82.
Idema AJ, Hoffmann AL, Boogaarts HD, Troost EG, Wesseling P, Heerschap A, et al. 3′-Deoxy-3′-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients. J Nucl Med. 2012;53:1904–10.CrossRefPubMed
83.
Tehrani OS, Shields AF. PET imaging of proliferation with pyrimidines. J Nucl Med. 2013;54:903–12.CrossRefPubMed
84.
Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, Rabinowitz P, et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 2002;8:3315–23.PubMed
85.
Tripathi M, Sharma R, D’Souza M, Jaimini A, Panwar P, Varshney R, et al. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med. 2009;34:878–83.CrossRefPubMed
86.
Shinomiya A, Kawai N, Okada M, Miyake K, Nakamura T, Kushida Y, et al. Evaluation of 3′-deoxy-3′-[18F]-fluorothymidine (18F-FLT) kinetics correlated with thymidine kinase-1 expression and cell proliferation in newly diagnosed gliomas. Eur J Nucl Med Mol Imaging. 2013;40:175–85.CrossRefPubMed
87.
Nowosielski M, DiFranco MD, Putzer D, Seiz M, Recheis W, Jacobs AH, et al. An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas. PLoS ONE. 2014;9: e95830.ADSCrossRefPubMedPubMedCentral
88.
Ferdova E, Ferda J, Baxa J, Tupy R, Mracek J, Topolcan O, et al. Assessment of grading in newly-diagnosed glioma using 18F-fluorothymidine PET/CT. Anticancer Res. 2015;35:955–9.PubMed
89.
Walsh JC, Lebedev A, Aten E, Madsen K, Marciano L, Kolb HC. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal. 2014;21:1516–54.CrossRefPubMedPubMedCentral
90.
Brown JM. Therapeutic targets in radiotherapy. Int J Radiat Oncol Biol Phys. 2001;49:319–26.CrossRefPubMed
91.
Hirata K, Yamaguchi S, Shiga T, Kuge Y, Tamaki N. The roles of hypoxia imaging using (18)F-fluoromisonidazole positron emission tomography in glioma treatment. J Clin Med. 2019;8:1088.
92.
Hammond EM, Asselin MC, Forster D, O’Connor JP, Senra JM, Williams KJ. The meaning, measurement and modification of hypoxia in the laboratory and the clinic. Clin Oncol (R Coll Radiol). 2014;26:277–88.CrossRefPubMed
93.
94.
Jerabek PA, Patrick TB, Kilbourn MR, Dischino DD, Welch MJ. Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue. Int J Rad Appl Instrum A. 1986;37:599–605.CrossRefPubMed
95.
Gronroos T, Bentzen L, Marjamaki P, Murata R, Horsman MR, Keiding S, et al. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:513–20.CrossRefPubMed
96.
Collet S, Guillamo JS, Berro DH, Chakhoyan A, Constans JM, Lechapt-Zalcman E, et al. Simultaneous mapping of vasculature, hypoxia, and proliferation using dynamic susceptibility contrast MRI, (18)F-FMISO PET, and (18)F-FLT PET in relation to contrast enhancement in newly diagnosed glioblastoma. J Nucl Med. 2021;62:1349–56.CrossRefPubMedPubMedCentral
97.
Reuss AM, Groos D, Buchfelder M, Savaskan N. The acidic brain-glycolytic switch in the microenvironment of malignant glioma. Int J Mol Sci. 2021;22:5518.
98.
Barajas RF Jr, Pampaloni MH, Clarke JL, Seo Y, Savic D, Hawkins RA, et al. Assessing biological response to bevacizumab using 18F-fluoromisonidazole PET/MR imaging in a patient with recurrent anaplastic astrocytoma. Case Rep Radiol. 2015;2015: 731361.PubMedPubMedCentral
Metadaten
Titel
Recent Update on PET/CT Radiotracers for Imaging Cerebral Glioma
verfasst von
Dongwoo Kim
Suk-Hyun Lee
Hee Sung Hwang
Sun Jung Kim
Mijin Yun
Publikationsdatum
21.02.2024
Verlag
Springer Nature Singapore
Erschienen in
Nuclear Medicine and Molecular Imaging
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-024-00847-4